Banque de Luxembourg S.A. Boosts Holdings in Becton, Dickinson and Company $BDX

Banque de Luxembourg S.A. grew its position in Becton, Dickinson and Company (NYSE:BDX) by 92.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 25,428 shares of the medical instruments supplier’s stock after purchasing an additional 12,235 shares during the quarter. Becton, Dickinson and Company comprises approximately 2.5% of Banque de Luxembourg S.A.’s investment portfolio, making the stock its 13th biggest holding. Banque de Luxembourg S.A.’s holdings in Becton, Dickinson and Company were worth $4,759,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Becton, Dickinson and Company by 15.4% in the 2nd quarter. Vanguard Group Inc. now owns 32,308,749 shares of the medical instruments supplier’s stock worth $5,565,182,000 after purchasing an additional 4,305,947 shares in the last quarter. Norges Bank purchased a new stake in Becton, Dickinson and Company in the second quarter valued at about $653,377,000. First Eagle Investment Management LLC boosted its holdings in Becton, Dickinson and Company by 59.2% in the second quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier’s stock worth $1,513,421,000 after acquiring an additional 3,268,478 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Becton, Dickinson and Company by 24.4% during the second quarter. Massachusetts Financial Services Co. MA now owns 8,514,446 shares of the medical instruments supplier’s stock worth $1,466,613,000 after acquiring an additional 1,670,590 shares during the last quarter. Finally, Laurel Wealth Advisors LLC increased its holdings in shares of Becton, Dickinson and Company by 16,974.4% during the second quarter. Laurel Wealth Advisors LLC now owns 1,579,386 shares of the medical instruments supplier’s stock valued at $272,049,000 after acquiring an additional 1,570,136 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $196.23 on Friday. The stock has a market capitalization of $55.91 billion, a PE ratio of 33.66, a price-to-earnings-growth ratio of 1.81 and a beta of 0.25. Becton, Dickinson and Company has a 52 week low of $162.29 and a 52 week high of $251.99. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69. The stock’s 50-day moving average price is $190.37 and its 200-day moving average price is $186.28.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The company had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%. As a group, equities analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 31st. Investors of record on Monday, December 8th will be issued a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Monday, December 8th. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s payout ratio is presently 72.04%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on BDX shares. Royal Bank Of Canada lifted their target price on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a research note on Wednesday, December 17th. Piper Sandler lowered their price objective on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday, November 7th. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Morgan Stanley raised their target price on Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Finally, Jefferies Financial Group boosted their price target on Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a research note on Wednesday, December 10th. Four analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $205.64.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of the stock in a transaction on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the transaction, the director directly owned 35,816 shares of the company’s stock, valued at $6,324,389.28. This trade represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 629 shares of the business’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $196.03, for a total transaction of $123,302.87. Following the sale, the executive vice president directly owned 13,105 shares of the company’s stock, valued at $2,568,973.15. This represents a 4.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 978 shares of company stock valued at $186,725 over the last 90 days. 0.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.